Actively Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Led by Shanghai Pharmaceuticals Holding Co., Ltd · Updated on 2025-08-17
170
Participants Needed
6
Research Sites
177 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.
CONDITIONS
Official Title
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Advanced solid tumors confirmed by tissue examination
- At least one measurable extracranial tumor lesion
- ECOG performance status score of 0 or 1
- Laboratory results meeting study standards during screening
- Life expectancy of at least 3 months
- Toxic reactions from previous cancer treatments returned to normal or grade 1 or lower
- Negative pregnancy test for women; males agree not to donate sperm; use of reliable contraception
- Willingness and ability to participate and complete all study procedures
You will not qualify if you...
- Recent anti-tumor treatments within specified time before first dose
- Previous treatment with drugs targeting the same mechanism
- Active infections requiring systemic therapy
- Uncontrolled fluid buildup that cannot be drained
- Severe or uncontrolled heart disease
- Severe lung disease
- Conditions affecting drug absorption, metabolism, or excretion
- Use of strong or moderate CYP3A4 inhibitors or inducers
- Long-term hormonotherapy use before screening
- Other cancers within past 5 years
- Symptomatic brain or spinal metastases
- Recent or planned major surgery or not yet recovered from surgery
- Abnormal viral tests or immune deficiency history
- Uncontrolled systemic illnesses
- Participation in other clinical trials with treatment within 21 days before first dose
- Use or planned use of live or attenuated vaccines within 28 days before first dose
- History of severe allergies to study drug or ingredients
- Inability to follow study protocol or complete visits and dosing
- History of alcohol or drug abuse
- Currently breastfeeding
- History of neurological or psychiatric disorders or other serious organ diseases
- Deemed unsuitable by investigator for other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
XiangYa Hospital CentralSouth University
Changsha, China
Actively Recruiting
2
Fujian Cancer Hospital
Fuzhou, China
Actively Recruiting
3
Zhejiang Cancer Hospital
Hangzhou, China
Actively Recruiting
4
Yunnan Cancer Hospital
Kunming, China
Actively Recruiting
5
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
6
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Actively Recruiting
Research Team
X
Xiaohua Wu
CONTACT
J
Jian Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here